The FDA on 18 January 2013 expanded the approved use of Botox (onabotulinumtoxinA) from Allergan, to treat adults with Overactive...
Toviaz (fesoterodine fumarate) from Pfizer has met its primary endpoint in Study A0221049.This was a 12 week trial which enrolled...
Allergan has submitted a supplemental BLA with the US FDA and an application with European regulatory authorities seeking approval of...
FDA has approved Anturol (oxybutynin) from Antares Pharma/Watson Pharma as a topical gel 3% for the treatment of Overactive Bladder...
The FDA has approved Myrbetriq (mirabegron) extended-release tablets, from Astellas, for the treatment of Overactive Bladder with symptoms of urge...
Positive results are anounced by AltheRx Pharma from its Phase II study of Solabegron in Overactive Bladder (OAB) at the...
The National Institute for Health and Care Excellence ( NICE) in England and Wales has issued final draft guidance recommending...
The Dutch Medicines Evaluation Board has granted marketing authorisation for Vesomni (solifenacin and tamsulosin), from Astellas, in the Netherlands for...
Betmiga (mirabegron), from Astellas, has received approval from the European Commission for the treatment of Overactive Bladder (OAB) symptoms in...
Astellas Pharma Inc. has announced that the Reproductive Health Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA)...